-
Mashup Score: 44Lipoprotein(a): Ready for Prime Time? - 3 month(s) ago
Author links open overlay panel Nathan D. Wong PhD, MPH Dr Wong has received research support through his institution from Novo Nordisk, Novartis, and Regeneron; and is a consultant for Novartis and Ionis. There are more references available in the full text version of this
Source: www.sciencedirect.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 25Evolution of More Aggressive LDL-Cholesterol Targets and Therapies for Cardiovascular Disease Prevention - 6 month(s) ago
Over the last half-century, discussions on the exact targets for low-density lipoprotein cholesterol (LDL-C) reduction have evolved towards a more aggressive approach with lower LDL-C targets, particularly for high-risk patients with pre-existing atherosclerotic cardiovascular disease (ASCVD). A wealth of cardiovascular outcome trials have shown the efficacy of statin therapy in general, as well as the incremental impact of high-intensity statin therapy in particular. More recent trials have further demonstrated the impact of non-statin therapies, including ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors, and, most recently, bempedoic acid, on reducing ASCVD outcomes. The availability of these and other newer therapies has prompted clinicians to strive for lower LDL-C targets to address residual ASCVD risk after statin therapy. This paper will provide an overview of the historical trends in lipid management and therapeutics and review the current state of evidence f
Source: www.mdpi.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 2ACC Launches New Quality Improvement and Education Program to Increase Cholesterol Screenings - American College of Cardiology - 8 month(s) ago
The ACC, through a strategic collaboration with Amgen and Esperion, is launching a new quality improvement campaign, “Driving Urgency in LDL Screening,” to increase the rate of diagnostic LDL screening in patients without a prior cardiac event as well as those with known cardiovascular disease to help clinicians identify those who need treatment in accordance with medical guidelines. “Cardiovascular disease is preventable in many cases, and early identification of risk is essential, especially for people
Source: www.acc.orgCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 4Wegovy could prevent up to 1.5 million heart attacks, strokes over 10 years, study says - 9 month(s) ago
The results complement the data Novo Nordisk released last week, which found Wegovy slashed the risk of serious heart problems and heart-related death by 20%.
Source: www.cnbc.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0Recent study at UC Irvine found that semaglutide medication may benefit 93 million U.S. adults - 9 month(s) ago
Researchers from the University of California, Irvine have just published a study that projects 93 million U.S. adults that are overweight and obese may be suit
Source: www.newswise.comCategories: Cardiologists, Latest HeadlinesTweet-
We project semaglutide 2.4 mg may benefit 93 million U.S. adults with overweight and obesity, resulting in 43 million fewer persons with obesity and 1.5 million fewer CVD events over 10 years with an estimated 18% risk reduction in those without prior CVD https://t.co/bHi4Bt94Ny https://t.co/rB7ebmryBt
-
-
Mashup Score: 0
Great snorkling just a few feet off the shore at the Sheraton Beach, perched on a reef dropping off some 30 feet or more just offshore. Puffers, angel fish…
Source: YouTubeCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0Is There a Role for Coronary Calcium in Patients With Diabetes? - 1 year(s) ago
In the primary prevention of atherosclerotic cardiovascular disease (ASCVD), a significant portion of high-risk patients have diabetes. Two decades ag…
Source: www.sciencedirect.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0
Treatment with SGLT2-is and GLP-1 RAs remains low, even among higher ASCVD risk persons with DM and use is even lower among underserved groups.
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 6Evolution of Coronary Calcium Screening for Assessment of Atherosclerotic Cardiovascular Disease Risk and Role in Preventive Cardiology - PubMed - 2 year(s) ago
Epidemiologic studies document a strong relation of age, race/ethnicity, and risk factors with the prevalence and extent of CAC. Large-scale registry and prospective investigations show CAC to be the strongest subclinical disease predictor of ASCVD outcomes, with higher CAC scores associated with su …
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 7Global Heart - 2 year(s) ago
Article: World Heart Federation Cholesterol Roadmap 2022
Source: globalheartjournal.comCategories: Cardiologists, Latest HeadlinesTweet
Lp(a): Ready for Prime Time? Our JACC editorial notes the failure to screen and identify Lp(a)-associated risks is a missed opportunity to address this risk with existing and possibly future therapies https://t.co/j3sqqC4XlF @ASPCardio @nationallipid @ucihealth @UCI_Cardiology